Nalmefene

Medical uses

Opioid overdose

Intravenous doses of nalmefene have been shown effective at counteracting the respiratory depression produced by opioid overdose.

Alcohol dependence

Nalmefene is used in the European Union to reduce alcohol dependence and NICE recommends the use of nalmefene to reduce alcohol consumption in combination with psychological support for people who drink heavily.

Based on a meta analysis, the usefulness of nalmefene for alcohol dependence is unclear. Nalmefene, in combination with psychosocial management, may decrease the amount of alcohol drunk by people who are alcohol dependent.

Side effects

Very common

The following side effects of nalmefene are very common (≥10% incidence):

• Insomnia
• Dizziness
• Headache
• Nausea

Common

The following side effects of nalmefene are common (≥1% to

• Decreased appetite
• Sleep disorder
• Confusional state
• Restlessness
• Libido decreased (including loss of libido)
• Somnolence
• Tremor
• Disturbance in attention
• Paraesthesia
• Hypoaesthesia
• Tachycardia
• Palpitations
• Vomiting
• Dry mouth
• Diarrhea
• Hyperhidrosis
• Muscle spasms
• Fatigue
• Asthenia
• Malaise
• Feeling abnormal
• Weight decreased

The majority of these reactions were mild or moderate, associated with treatment initiation, and of short duration.

Pharmacology

Pharmacodynamics

Opioid receptor blockade

Nalmefene acts as an inverse agonist of the μ-opioid receptor (MOR) ( = 0.24 nM) and as a weak partial agonist (Ki = 0.083 nM; Emax = 20–30%) of the κ-opioid receptor (KOR), with similar binding for these two receptors but a several-fold preference for the KOR. In another study however, nalmefene had approximately equal affinity for the MOR and KOR. In vivo evidence indicative of KOR activation, such as elevation of serum prolactin levels due to dopamine suppression and increased hypothalamic–pituitary–adrenal axis activation via enhanced adrenocorticotropic hormone and cortisol secretion, has been observed in humans and animals. Side effects typical of KOR activation such as hallucinations and dissociation have also been observed with nalmefene in human studies. It is thought that nalmefene activation of KOR may produce dysphoria and anxiety. In addition to MOR and KOR binding, nalmefene also possesses some, albeit far lower affinity for the δ-opioid receptor (DOR) (Ki = 16 nM), where it behaves as an antagonist.

Nalmefene is structurally related to naltrexone and differs from it by substitution of the ketone group at the C6 position of naltrexone with a methylene group (CH2). It binds to the MOR with similar affinity relative to naltrexone, but binds "somewhat more avidly" to the KOR and DOR in comparison.

Nalmefene with a single 1 mg dose by intravenous injection has been found to produce brain MOR blockade of 99% at 5 minutes, 90% at 2 hours, 33% at 4 hours, and 10% at 8 hours. A lower dose of 1 μg/kg intravenously resulted in brain MOR blockade of 52% at 5 minutes, 33% at 2 hours, 47% at 4 hours, and 26% at 8 hours. With oral administration, peak brain MOR occupancy of 87 to 100% was found after 3 hours with single or repeated dosing of nalmefene. At 26 hours (1.1 days) post-administration, brain MOR occupancy was 83 to 100%; at 50 hours (2.1 days), it was 48 to 72%; and at 74 hours (3.1 days), it was 12 to 46%. The half-time of nalmefene occupancy of brain MORs is about 29 hours and is much longer than with naloxone. Substantial brain MOR occupancy occurs with nalmefene even when blood levels of nalmefene are very low. The prolonged brain MOR occupancy of nalmefene may be due to slow dissociation of nalmefene from MORs consequent to its high MOR affinity.

Metabolism

Nalmefene is extensively metabolized in the liver, mainly by conjugation with glucuronic acid and also by N-dealkylation. Less than 5% of the dose is excreted unchanged. The glucuronide metabolite is entirely inactive, while the N-dealkylated metabolite has minimal pharmacological activity.

Chemistry

Nalmefene is a derivative of naltrexone and was first reported in 1975.

Society and culture

Nalmefene was first reported in a patent in 1974.

Legal status

United States

In the United States, immediate-release injectable nalmefene was approved in 1995, as an antidote for opioid overdose. It was sold under the brand name Revex. The product was discontinued by its manufacturer around 2008. A generic version was approved for medical use in the United States in February 2022.

In May 2023, the Food and Drug Administration (FDA) approved a nalmefene hydrochloride nasal spray, under the brand name Opvee, for the emergency treatment of opioid overdose in people aged twelve years of age and older.

In August 2024, the FDA approved a nalmefene hydrochloride auto-injector (Zurnai) for the emergency treatment of known or suspected opioid overdose in people aged twelve years of age and older. The FDA granted the application for the nalmefene hydrochloride auto-injector fast track and priority review designations. The FDA granted approval of Zurnai to Purdue Pharma L.P.

As of 2012, nalmefene in pill form, used for the treatment of alcohol dependence and other addictive behaviors, is not available in the United States.

European Union

Danish pharmaceutical company Lundbeck has licensed nalmefene from Biotie Therapies and performed clinical trials with nalmefene for treatment of alcohol dependence. In 2011, they submitted an application for their medication named Selincro to the European Medicines Agency. The medication was authorized for use in the EU in March 2013. and in October 2013, Scotland became the first country in the EU to prescribe the drug for alcohol dependence. England followed Scotland by offering the medication as a treatment for problem drinking in October 2014. In November 2014, nalmefene was approved as a possible treatment supplied by Britain's National Health Service (NHS) for reducing alcohol consumption in people with alcohol dependence.

Research

Oral nalmefene was under development for the treatment of pathological gambling, interstitial cystitis, pruritus, rheumatoid arthritis, shock, and smoking withdrawal, but development was discontinued for all of these indications. Formulations of nalmefene for use by intramuscular injection, intravenous injection, and intranasal administration are in late-stage development for the treatment of opioid-related disorders.

Nalmefene might be useful to treat cocaine addiction.

References

References

1. (21 June 2022). "Prescription medicines: registration of new chemical entities in Australia, 2015".
2. "Revex- nalmefene hydrochloride injection, solution".
3. (19 June 2023). "Opvee- nalmefene hydrochloride spray".
4. (August 2024). "Prescribing Label - Zurnai".
5. (13 March 2013). "Selincro EPAR".
6. (February 2016). "Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy". Wiley.
7. (23 May 2023). "FDA Approves Prescription Nasal Spray to Reverse Opioid Overdose".
8. (24 March 2020). "LiverTox: Clinical and Research Information on Drug-Induced Liver Injury". [[National Library of Medicine]].
9. (11 February 2022). "Competitive Generic Therapy Approvals".
10. (September 2016). "Selincro 18mg film-coated tablets". UK Electronic Medicines Compendium.
11. (26 November 2014). "Technology appraisal guidance [TA325]: Nalmefene for reducing alcohol consumption in people with alcohol dependence". NICE.
12. (December 2015). "Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials". PLOS Medicine.
13. (2014). "Nalmefene: a new approach to the treatment of alcohol dependence". Substance Abuse and Rehabilitation.
14. "Selincro".
15. (March 1998). "Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications". NIDA Res Monogr.
16. (October 2019). "The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence". Biol Psychiatry.
17. (December 2005). "Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?". Neuropsychopharmacology.
18. Linda P. Dwoskin. (29 January 2014). "Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse". Elsevier Science.
19. (October 2013). "Targeted opioid receptor antagonists in the treatment of alcohol use disorders". CNS Drugs.
20. (June 2014). "Nalmefene. Alcohol dependence: no advance". Prescrire International.
21. (15 May 2014). "Prescriber's guide: Stahl's essential psychopharmacology". Cambridge University Press.
22. (July 2015). "Treatment of cocaine craving with as-needed nalmefene, a partial κ opioid receptor agonist: first clinical experience". International Clinical Psychopharmacology.
23. (2013). "Biological Research on Addiction". Elsevier.
24. (November 2010). "Nalmefene for treatment of alcohol dependence". Expert Opin Investig Drugs.
25. (December 2005). "Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing". Neuropsychopharmacology.
26. (November 1997). "Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system". J Nucl Med.
27. (2014). "Drug Discovery for the Treatment of Addiction: Medicinal Chemistry Strategies". John Wiley & Sons.
28. {{US Patent. 3814768
29. "Nalmefene label". U.S. Food and Drug Administration.
30. (9 July 2008). "Baxter discontinues Revex injection". Haymarket Media, Inc.
31. "Drug Shortages". U.S. [[Food and Drug Administration]] (FDA).
32. (3 November 2017). "Determination That Revex (Nalmefene Hydrochloride Injection), 0.1 Milligram Base/Milliliter and 1.0 Milligram Base/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness".
33. "Nalmefene hydrochloride: FDA-Approved Drugs".
34. (7 August 2024). "FDA Approves First Nalmefene Hydrochloride Auto-Injector to Reverse Opioid Overdose".
35. {{ClinicalTrialsGov. NCT00811720. Efficacy of nalmefene in patients with alcohol dependence (ESENSE1
36. (22 December 2011). "Lundbeck submits Selincro in EU; Novo Nordisk files Degludec in Japan". The Pharma Letter.
37. (13 March 2013). "Selincro". European Medicines Agency.
38. (7 October 2013). "Alcohol cravings drug nalmefene granted approval in Scotland". BBC News.
39. (3 October 2014). "Nalmefene granted approval in England". The Independent.
40. (26 November 2014). "Alcohol dependence treatment accepted for NHS use". MIMS.
41. "Nalmefene oral - Acorda Therapeutics/Lundbeck A/S". Springer Nature Switzerland AG.
42. "Nalmefene hydrochloride injection - Purdue Pharma". Springer Nature Switzerland AG.
43. "Intranasal nalmefene - Opiant Pharmaceuticals". Springer Nature Switzerland AG.
44. (2014). "Mixed κ/μ partial opioid agonists as potential treatments for cocaine dependence". Elsevier.